{"id":1055,"date":"2023-04-12T11:43:25","date_gmt":"2023-04-12T11:43:25","guid":{"rendered":"https:\/\/www.cic.vc\/?p=1055"},"modified":"2023-12-14T15:42:34","modified_gmt":"2023-12-14T15:42:34","slug":"microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/","title":{"rendered":"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma"},"content":{"rendered":"<p><span class=\"text-small\"><a href=\"https:\/\/microbiotica.com\/\" target=\"_blank\" rel=\"noopener\">Microbiotica<\/a>, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck &amp; Co., Inc., Rahway, NJ, USA).<\/span><\/p>\n<p><span class=\"text-small\">Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical activity of its live biotherapeutic product, MB097, in combination with KEYTRUDA\u00ae (pembrolizumab), MSD\u2019s anti-PD-1 therapy, in melanoma patients with primary resistance to an anti-PD-1-containing immunotherapy. Microbiotica will be the study sponsor and MSD will supply KEYTRUDA\u00ae.<\/span><\/p>\n<p><span class=\"text-small\">MB097 is an orally administered live biotherapeutic product consisting of a defined consortium of nine bacterial strains designed to enhance the efficacy of immune checkpoint inhibitors (ICIs) such as KEYTRUDA\u00ae.<\/span><\/p>\n<p><span class=\"text-small\">The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma. Microbiotica\u2019s discovery platform facilitates precise, strain-level identification of bacterial signatures associated with clinical response. Moreover, MB097 displayed potent anti-tumour efficacy in combination with ICIs in in vivo tumour models and demonstrated multiple immuno-stimulatory mechanisms in primary human immune cell assays including Cytotoxic T Lymphocyte activation and tumour cell killing in vitro.<\/span><\/p>\n<p><span class=\"text-small\"><strong>Tim Sharpington, CEO of Microbiotica, said:<\/strong><\/span><\/p>\n<p>&#8220;We are delighted to be working with MSD, a world leader in immuno-oncology. The treatment of patients with advanced melanoma has been revolutionised by ICIs such as KEYTRUDA\u00ae and there is an opportunity to increase the number of patients who can benefit from these treatments. There is growing evidence that the gut microbiome plays a critical role in determining a patient\u2019s response to ICIs and we believe that MB097, in combination with KEYTRUDA\u00ae, has the potential to enhance the benefit for patients with advanced melanoma and other difficult-to-treat cancers.&#8221;<\/p>\n<p><span class=\"text-small\">(KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.)<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck &amp; Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[6,29],"tags":[49],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck &amp; Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T11:43:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-14T15:42:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background-1024x768.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lewis Harrison-Pinder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lewis Harrison-Pinder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/\",\"url\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/\",\"name\":\"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png\",\"datePublished\":\"2023-04-12T11:43:25+00:00\",\"dateModified\":\"2023-12-14T15:42:34+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png\",\"width\":1600,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\",\"name\":\"Lewis Harrison-Pinder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"caption\":\"Lewis Harrison-Pinder\"},\"url\":\"https:\/\/www.cic.vc\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/","og_locale":"en_GB","og_type":"article","og_title":"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital","og_description":"Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD (Merck &amp; Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical [&hellip;]","og_url":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-04-12T11:43:25+00:00","article_modified_time":"2023-12-14T15:42:34+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background-1024x768.png","type":"image\/png"}],"author":"Lewis Harrison-Pinder","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Lewis Harrison-Pinder","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/","url":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/","name":"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png","datePublished":"2023-04-12T11:43:25+00:00","dateModified":"2023-12-14T15:42:34+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Microbiotica-white-logo-on-background.png","width":1600,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/microbiotica-announces-collaboration-with-msd-in-a-phase-1b-clinical-trial-in-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanoma"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc","name":"Lewis Harrison-Pinder","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","caption":"Lewis Harrison-Pinder"},"url":"https:\/\/www.cic.vc\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1055"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=1055"}],"version-history":[{"count":2,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1055\/revisions"}],"predecessor-version":[{"id":3013,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1055\/revisions\/3013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/1357"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=1055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=1055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=1055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}